ClinicalTrials.gg
CompletedNCT02731131Updated Jul 15, 2016Results posted

A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)

A Phase 2 interventional study of Peginterferon alfa-2a and Ribavirin in Hepatitis D, Chronic, sponsored by Hoffmann-La Roche. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-15.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Hepatitis D, Chronic with a site in Italy — 3 open to participants now, 6 under way, 2 of them phase 3. Hepatitis D, Chronic · Italy.

Started
2004
the only one that year
Phase 2
4 of 10
1 open now
Registered
1st of 10
by date
Lead sponsor
1 of 10
Hoffmann-La Roche

Among the 10 studies in Hepatitis D, Chronic with a site in Italy, this one is the only one that started in 2004, is one of 4 in phase 2, and was the 1st registered.

Hepatitis D, Chronic

43 studies on the registry are indexed under Hepatitis D, Chronic; 9 are open to participants now.

Browse Hepatitis D, Chronic studies →

Open to participants now

3 of the 10 studies in Hepatitis D, Chronic with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 6 Hepatitis D, Chronic studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hepatitis D, Chronic with a site in Italy, or all of them as a file.
02

Study summary

This single-center, randomized, open-label, pilot study is designed to evaluate the efficacy and safety of 48 weeks of treatment with peginterferon alfa-2a alone versus in combination with ribavirin in participants with CHD.

03

Conditions studied

  • Hepatitis D, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive surface antigen (HBsAg) for the prior 6 months
  • Positive anti-delta for the prior 3 months
  • Positive HDV RNA at Screening
  • Elevated (1 to 10 times ) prior to first dose
  • Chronic, necroinflammatory hepatitis documented within the prior 18 months (non-cirrhotic) or 30 months (cirrhotic)
  • Negative pregnancy and adequate use

Exclusion criteria

Exclusion Criteria:

  • Antiviral therapy for CHD within previous 3 months
  • Positive for hepatitis A or C, or (HIV)
  • Increased risk of metabolic liver disease
  • Decompensated liver disease
  • Elevated
  • Poor hematologic or renal function
  • Drug/alcohol abuse within 1 year prior to study
  • History of significant psychiatric, , pulmonary, cardiac, oncologic, or thyroid disease
  • Organ transplantation with existing functional graft
  • Retinopathy or other ophthalmologic complication of diabetes or hypertension
  • Inclusion in another trial within previous 12 weeks
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Group A: Monotherapy with Peginterferon alfa-2a

    Participants will receive peginterferon alfa-2a alone, administered over 48 weeks.

    Drug: Peginterferon alfa-2a

  • Experimental
    Group B: Combination with Peginterferon alfa-2a + Ribavirin

    Participants will receive combination therapy with peginterferon alfa-2a plus ribavirin, administered over 48 weeks.

    Drug: Peginterferon alfa-2a · Drug: Ribavirin

Interventions

  • Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.

    Also known as: Pegasys

  • Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.

    Also known as: Copegus

06

What researchers measure

Primary outcomes

  1. Number of Participants With Alanine Aminotransferase (ALT) Normalization Plus Negative Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) at 48 Weeks After End of Treatment

    Normalized ALT was defined as ALT value above the upper limit of normal (ULN) at Baseline with a decrease in ALT value to at/below the ULN at 48 weeks after end of treatment (Week 96). Negative HDV RNA was defined as HDV RNA not detected by polymerase chain reaction (PCR). The number of participants with ALT normalization and negative HDV RNA at Week 96 was reported.

    Time frame: Week 96

Secondary outcomes

  1. Number of Participants With ALT Normalization Plus Negative HDV RNA at End of Treatment

    Normalized ALT was defined as ALT value above the ULN at Baseline with a decrease in ALT value to at/below the ULN at the end of treatment (Week 48). Negative HDV RNA was defined as HDV RNA not detected by PCR. The number of participants with ALT normalization and negative HDV RNA at Week 48 was reported.

    Time frame: Week 48

  2. Number of Participants With ALT Normalization at 48 Weeks After End of Treatment

    Normalized ALT was defined as ALT value above the ULN at Baseline with a decrease in ALT value to at/below the ULN at 48 weeks after end of treatment (Week 96). The number of participants with ALT normalization at Week 96 was reported.

    Time frame: Week 96

  3. Number of Participants With ALT Normalization at End of Treatment

    Normalized ALT was defined as ALT value above the ULN at Baseline with a decrease in ALT value to at/below the ULN at the end of treatment (Week 48). The number of participants with ALT normalization at Week 48 was reported.

    Time frame: Week 48

  4. Number of Participants With Negative HDV RNA at 48 Weeks After End of Treatment

    Negative HDV RNA was defined as HDV RNA not detected by PCR. The number of participants with negative HDV RNA at 48 weeks after end of treatment (Week 96) was reported.

    Time frame: Week 96

  5. Number of Participants With Negative HDV RNA at End of Treatment

    Negative HDV RNA was defined as HDV RNA not detected by PCR. The number of participants with negative HDV RNA at the end of treatment (Week 48) was reported.

    Time frame: Week 48

07

Results

Posted Jul 15, 2016

Participant flow

Participant flow — Overall Study
MilestoneGroup A: Monotherapy With Peginterferon Alfa-2aGroup B: Combination With Peginterferon Alfa-2a + Ribavirin
Started66
Completed64
Not completed02
Withdrew: Psychiatric disorder01
Withdrew: Refused therapy01

Outcome measures

PrimaryNumber of Participants With Alanine Aminotransferase (ALT) Normalization Plus Negative Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) at 48 Weeks After End of Treatment

Normalized ALT was defined as ALT value above the upper limit of normal (ULN) at Baseline with a decrease in ALT value to at/below the ULN at 48 weeks after end of treatment (Week 96). Negative HDV RNA was defined as HDV RNA not detected by polymerase chain reaction (PCR). The number of participants with ALT normalization and negative HDV RNA at Week 96 was reported.

Time frame:
Week 96
Reported as:
Number · participants
Number of Participants With Alanine Aminotransferase (ALT) Normalization Plus Negative Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) at 48 Weeks After End of Treatment
participantsGroup A: Monotherapy With Peginterferon Alfa-2aGroup B: Combination With Peginterferon Alfa-2a + Ribavirin
Number of Participants With Alanine Aminotransferase (ALT) Normalization Plus Negative Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) at 48 Weeks After End of Treatment01
Statistical analysis
  • Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin · Fisher Exact · p = 0.30
SecondaryNumber of Participants With ALT Normalization Plus Negative HDV RNA at End of Treatment

Normalized ALT was defined as ALT value above the ULN at Baseline with a decrease in ALT value to at/below the ULN at the end of treatment (Week 48). Negative HDV RNA was defined as HDV RNA not detected by PCR. The number of participants with ALT normalization and negative HDV RNA at Week 48 was reported.

Time frame:
Week 48
Reported as:
Number · participants
Number of Participants With ALT Normalization Plus Negative HDV RNA at End of Treatment
participantsGroup A: Monotherapy With Peginterferon Alfa-2aGroup B: Combination With Peginterferon Alfa-2a + Ribavirin
Number of Participants With ALT Normalization Plus Negative HDV RNA at End of Treatment00
SecondaryNumber of Participants With ALT Normalization at 48 Weeks After End of Treatment

Normalized ALT was defined as ALT value above the ULN at Baseline with a decrease in ALT value to at/below the ULN at 48 weeks after end of treatment (Week 96). The number of participants with ALT normalization at Week 96 was reported.

Time frame:
Week 96
Reported as:
Number · participants
Number of Participants With ALT Normalization at 48 Weeks After End of Treatment
participantsGroup A: Monotherapy With Peginterferon Alfa-2aGroup B: Combination With Peginterferon Alfa-2a + Ribavirin
Number of Participants With ALT Normalization at 48 Weeks After End of Treatment31
Statistical analysis
  • Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin · Fisher Exact · p = 0.22
SecondaryNumber of Participants With ALT Normalization at End of Treatment

Normalized ALT was defined as ALT value above the ULN at Baseline with a decrease in ALT value to at/below the ULN at the end of treatment (Week 48). The number of participants with ALT normalization at Week 48 was reported.

Time frame:
Week 48
Reported as:
Number · participants
Number of Participants With ALT Normalization at End of Treatment
participantsGroup A: Monotherapy With Peginterferon Alfa-2aGroup B: Combination With Peginterferon Alfa-2a + Ribavirin
Number of Participants With ALT Normalization at End of Treatment10
Statistical analysis
  • Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin · Fisher Exact · p = 0.30
SecondaryNumber of Participants With Negative HDV RNA at 48 Weeks After End of Treatment

Negative HDV RNA was defined as HDV RNA not detected by PCR. The number of participants with negative HDV RNA at 48 weeks after end of treatment (Week 96) was reported.

Time frame:
Week 96
Reported as:
Number · participants
Number of Participants With Negative HDV RNA at 48 Weeks After End of Treatment
participantsGroup A: Monotherapy With Peginterferon Alfa-2aGroup B: Combination With Peginterferon Alfa-2a + Ribavirin
Number of Participants With Negative HDV RNA at 48 Weeks After End of Treatment01
Statistical analysis
  • Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin · Fisher Exact · p = 0.30
SecondaryNumber of Participants With Negative HDV RNA at End of Treatment

Negative HDV RNA was defined as HDV RNA not detected by PCR. The number of participants with negative HDV RNA at the end of treatment (Week 48) was reported.

Time frame:
Week 48
Reported as:
Number · participants
Number of Participants With Negative HDV RNA at End of Treatment
participantsGroup A: Monotherapy With Peginterferon Alfa-2aGroup B: Combination With Peginterferon Alfa-2a + Ribavirin
Number of Participants With Negative HDV RNA at End of Treatment12
Statistical analysis
  • Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin · Fisher Exact · p = 0.50

Adverse events

Collected over Baseline through 24 weeks after end of treatment (up to 72 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: Monotherapy With Peginterferon Alfa-2a—0/6 (0%)6/6 (100%)
Group B: Combination With Peginterferon Alfa-2a + Ribavirin—0/6 (0%)6/6 (100%)
Most frequent other events
Showing 10 of 41
Most frequent other events
EventGroup A: Monotherapy With Peginterferon Alfa-2aGroup B: Combination With Peginterferon Alfa-2a + Ribavirin
AstheniaGeneral disorders5/63/6
PyrexiaGeneral disorders5/63/6
ArthralgiaMusculoskeletal and connective tissue disorders5/62/6
MyalgiaMusculoskeletal and connective tissue disorders4/62/6
InsomniaPsychiatric disorders4/63/6
AnxietyPsychiatric disorders0/64/6
HeadacheNervous system disorders3/62/6
DepressionPsychiatric disorders2/63/6
IrritabilityPsychiatric disorders2/63/6
CoughRespiratory, thoracic and mediastinal disorders3/62/6

Baseline characteristics

Intent-to-Treat (ITT) Population: All participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Group A: Monotherapy With Peginterferon Alfa-2aGroup B: Combination With Peginterferon Alfa-2a + RibavirinTotal
Mean47.2 ± 9.249.2 ± 7.448.2 ± 8.0
Sex: Female, Male
Sex: Female, Male(Participants)Group A: Monotherapy With Peginterferon Alfa-2aGroup B: Combination With Peginterferon Alfa-2a + RibavirinTotal
Female101
Male5611
08

Study locations

1 site
  • Cagliari, 09042, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 7 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2016
First posted
Apr 7, 2016
Start
Sep 2004
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Jul 15, 2016
Last update
Jul 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02731131
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 7, 2016
Start date
Sep 2004
Primary completion
May 2009
Completion
May 2009
Results posted
Jul 15, 2016
Last update
Jul 15, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion